AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
BRIDGEWATER, N.J. and CINCINNATI, Sept. 28 /PRNewswire/ -- The Alliance for Better Bone Health announced its response to the results of Merck's bone mineral density (BMD) study released today.
"Bone mineral density (BMD) is important for determining if a patient needs therapy, but when determining which therapy, fracture reduction is the clinically relevant endpoint," says Dr. Nora Zorich, M.D., Ph.D., Head of Drug Development, P&G Pharmaceuticals. "If Merck had intended to fully compare efficacy, they would have run a head-to-head fracture trial."
Merck's own vice president of clinical research was quoted to this effect in response to another ...